NDA 219757 · Rosemont Pharms
Vostally
Ramipril · Oral
DiscontinuedLast checked: Nov 20, 2026Latest source record: Jul 23, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Jul 23, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
188
53 Phase 3, 15 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- VOSTALLY · RAMIPRIL 1MG/ML · SOLUTION, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Ramipril" as an intervention, any sponsor and status, largest first.
Boehringer IngelheimBoehringer Ingelheim
NCT00153101 · 31,546 participants · Start Nov 2001 · Primary completion Jun 2008
Drug: Telmisartan; Combination of Telmisartan and Ramipril and 1 more · For: Cardiovascular Diseases
Sites: Athens, Alabama; Birmingham, Alabama; Phoenix, Arizona · 732 sites in all
- Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk AssessmentPivotal-lookingCompleted
University of VigoAcademic, hospital or other
NCT00741585 · 21,983 participants · Start Sep 1, 2008 · Primary completion Jun 30, 2018
Drug: Any antihypertensive medication alone or in combination; Any antihypertensive medication alone or in combination · For: Essential Hypertension; Cardiovascular Disease; Stroke and 1 more
Sites: Friol, Spain; A Estrada, Spain; Baiona, Spain · 20 sites in all
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
- Action to Control Cardiovascular Risk in Diabetes (ACCORD)Pivotal-lookingCompleted
National Heart, Lung, and Blood Institute (NHLBI)NIH
NCT00000620 · 10,251 participants · Start Sep 1999 · Primary completion Jun 2009
Drug: Anti-hyperglycemic Agents; Anti-hypertensive Agents and 1 more · For: Atherosclerosis; Cardiovascular Diseases; Hypercholesterolemia and 4 more
Sites: Minneapolis, Minnesota; New York, New York; Winston-Salem, North Carolina · 7 sites in all
- The International Polycap Study 3 (TIPS-3)Pivotal-lookingCompleted
Population Health Research InstituteAcademic, hospital or other
NCT01646437 · 7,793 participants · Start Jun 2012 · Primary completion Jun 30, 2020
Drug: Polycap; Aspirin and 2 more · For: Cardiovascular Disease; Fractures; Cancers
Sites: Dhaka, Bangladesh; Hamilton, Canada; Bucaramanga, Colombia · 9 sites in all
- Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MIPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT02924727 · 5,669 participants · Start Dec 9, 2016 · Primary completion Feb 26, 2021
Drug: LCZ696 (sacubitril/valsartan); Ramipril and 4 more · For: Acute Myocardial Infarction
Sites: Birmingham, Alabama; Huntsville, Alabama; Gilbert, Arizona · 486 sites in all
- The DREAM (Diabetes Reduction Assessment With Ramipril and Rosiglitazone Medication) TrialPivotal-lookingCompleted
Gerstein, Hertzel, MDIndividual
NCT00095654 · 5,000 participants · Start Jul 2001
Drug: Ramipril; Rosiglitazone · For: Impaired Glucose Tolerance; Cardiovascular Disease; Glucose Metabolism Disorders
- Secondary Prevention of Cardiovascular Disease in the Elderly TrialPivotal-lookingCompleted
Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos IIIAcademic, hospital or other
NCT02596126 · 2,499 participants · Start Jul 2016 · Primary completion Oct 31, 2021
Drug: Cardiovascular Polypill; Treatment Prevention for Secondary CV · For: Myocardial Infarction; Cardiovascular Disease
Sites: Prague, Czechia; Benešov, Czechia; Jihlava, Czechia · 113 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Angiotensin-converting enzyme inhibitor induced cough compared with placebo, and other antihypertensives: A systematic review, and network meta-analysis.
Hu Y, Liang L, Liu S, et al. · J Clin Hypertens (Greenwich) 2023 · Systematic Review, Network Meta-Analysis
- Polypill Strategy in Secondary Cardiovascular Prevention.
Castellano JM, Pocock SJ, Bhatt DL, et al. · N Engl J Med 2022 · Clinical Trial, Phase III, Randomized Controlled Trial
- The DIAB-HYCAR Study.
Passa P, Chatellier G · Diabetologia 1996 · Clinical Trial, Randomized Controlled Trial
- Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.
Yusuf S, Sleight P, Pogue J, et al. · N Engl J Med 2000 · Clinical Trial, Multicenter Study
- Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction.
Pfeffer MA, Claggett B, Lewis EF, et al. · N Engl J Med 2021 · Comparative Study, Multicenter Study
- [Critically appraised article].
Neumann I, Grassi B · Rev Med Chil 2012 · Randomized Controlled Trial
Sponsor: Rosemont Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.